VCRE
Vicore Pharma Holding AB
9.30$
-1.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 24 | Q1 25 | Q2 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|
| – | -82.5% | +95.7% | -76.0% | +43.7% | +267.6% | – | |
| – | -82.5% | +95.7% | -76.0% | +43.7% | +267.6% | – | |
| – | -3.5% | +26.3% | +13.7% | -9.2% | +15.8% | – | |
| – | -16.7% | -0.3% | +56.7% | -2.5% | +53.5% | – | |
| – | -6.8% | +22.2% | +18.8% | -7.2% | +22.4% | – | |
| – | – | – | – | – | – | – | |
| – | +2,640,400.0% | -45.1% | -41.1% | -92.5% | -99.8% | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.